Artiva biotherapeutics reports second quarter 2025 financial results, recent business highlights

First patient treated in company-sponsored global basket trial exploring allonk® + rituximab in refractory rheumatoid arthritis, sjÖgren's disease, idiopathic inflammatory myopathies, and systemic sclerosis continued execution and enrollment progress with over a dozen patients treated with allonk + mab across over a dozen sites in company-sponsored and investigator-initiated clinical trials in autoimmune diseases initial safety, translational data, and lead indication selection for allonk in autoimmune diseases to be presented by year-end 2025; initial clinical response data in the lead indication to be presented in 1h2026 cash runway into q2 2027, with cash, cash equivalents, and investments of $142.4 million as of june 30, 2025 san diego, aug. 06, 2025 (globe newswire) -- artiva biotherapeutics, inc. (nasdaq: artv) (artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced financial results for the second quarter ended june 30, 2025, and highlighted recent progress. “we are making meaningful progress across our ongoing clinical trials exploring allonk® in autoimmune disease.
ARTV Ratings Summary
ARTV Quant Ranking